Source: Annual Congress 2013 –ME3 Biomarkers for fibrotic lung disease – new clinical benchmarks from the lab?



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kolb (Hamilton, Canada). Biomarkers for fibrotic lung disease - new clinical benchmarks from the lab?. Annual Congress 2013 –ME3 Biomarkers for fibrotic lung disease – new clinical benchmarks from the lab?

Member's Comments

No comment yet.

Related content which might interest you: Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021 Determining genomic rearrangements in clinical lung specimens for assessment of metastatic disease, actionable targets and disease monitoring Source: International Congress 2016 – New genomic targets in pulmonary disease Year: 2016 A pragmatic clinical classification for interstitial lung disease Source: Annual Congress 2012 - Reclassification of idiopathic interstitial pneumonias Year: 2012 Computed-tomography-based radiomics features for staging of interstitial lung disease – transferability from experimental to human lung fibrosis - a proof-of-concept study Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update Year: 2019 An international survey on genetics in clinical practice for interstitial lung disease. Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 Interims analysis of the EXCITING-ILD registry (registry for exploring clinical and epidemiological characteristics of interstitial lung diseases) Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Role of lung biopsies in the diagnosis of interstitial lung diseases in a clinical real-life setting Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Multidisciplinary board for interstitial lung disease: Relevance for real life? Source: International Congress 2015 – New insights into IIPs Year: 2015 Biomarker discovery, development, and implementation in interstitial lung diseases Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021 Clinical use of interstitial lung disease guidelines Source: Eur Respir Mon; 2009: 46: 386–395 Year: 2009 Smoking-related lung diseases: a clinical perspective Source: Eur Respir J 2010; 35: 231-233 Year: 2010 Recommendations for epidemiological studies on COPD Source: Eur Respir J 2011; 38: 1261-1277 Year: 2011 Human small airway-on-a-chip: A novel microphysiological system to model lung inflammation, accelerate drug development and enable inhalational toxico-analysis Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 Use of national disease registries in the conduct of long-term post-authorisation drug safety studies (LTSSs) Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Global characterisation of routine care interstitial lung disease diagnostic practice Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 Monitoring early lung disease in cystic fibrosis: where are we now? Source: Breathe 2014; 10: 34-47 Year: 2014 Interstitial lung disease: new challenges and evolving phenotypes Source: Eur Respir Rev 2009; 19: 91-93 Year: 2010